SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Samantha J. Podurgiel, Tiahna Spencer, Rotem Kovner, Younis Baqi, Christa E. Müller, Merce Correa, John D. Salamone, Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine: Reversal with adenosine A2A antagonism, Pharmacology Biochemistry and Behavior, 2016, 140, 62

    CrossRef

  2. 2
    Tomoyoshi Kondo, Yoshikuni Mizuno, A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease, Clinical Neuropharmacology, 2015, 38, 2, 41

    CrossRef

  3. 3
    Emmanuelle Pourcher, Philippe Huot, Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease, Movement Disorders Clinical Practice, 2015, 2, 4
  4. 4
    Zhi-jun Li, Qian Wu, Chen-ju Yi, Clinical efficacy of istradefylline versus rTMS on Parkinson’s disease in a randomized clinical trial, Current Medical Research and Opinion, 2015, 31, 11, 2055

    CrossRef

  5. 5
    Yingqun Tao, Guobiao Liang, Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson’s Disease: A Meta-analysis of Randomized Controlled Trials, Cell Biochemistry and Biophysics, 2015, 71, 1, 57

    CrossRef

  6. 6
    Diego Guidolin, Luigi F Agnati, Manuela Marcoli, Dasiel O Borroto-Escuela, Kjell Fuxe, G-protein-coupled receptor type A heteromers as an emerging therapeutic target, Expert Opinion on Therapeutic Targets, 2015, 19, 2, 265

    CrossRef

  7. 7
    Delia Preti, Pier Giovanni Baraldi, Allan R. Moorman, Pier Andrea Borea, Katia Varani, History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents, Medicinal Research Reviews, 2015, 35, 4
  8. 8
    Morteza Abdoli, Zohreh Mirjafary, Hamid Saeidian, Ali Kakanejadifard, New developments in direct functionalization of C–H and N–H bonds of purine bases via metal catalyzed cross-coupling reactions, RSC Adv., 2015, 5, 55, 44371

    CrossRef

  9. 9
    Gengyang Yuan, Nicholas G Gedeon, Tanner C Jankins, Graham B Jones, Novel approaches for targeting the adenosine A2Areceptor, Expert Opinion on Drug Discovery, 2015, 10, 1, 63

    CrossRef

  10. 10
    Matthieu F. Bastide, Wassilios G. Meissner, Barbara Picconi, Stefania Fasano, Pierre-Olivier Fernagut, Michael Feyder, Veronica Francardo, Cristina Alcacer, Yunmin Ding, Riccardo Brambilla, Gilberto Fisone, A. Jon Stoessl, Mathieu Bourdenx, Michel Engeln, Sylvia Navailles, Philippe De Deurwaerdère, Wai Kin D. Ko, Nicola Simola, Micaela Morelli, Laurent Groc, Maria-Cruz Rodriguez, Eugenia V. Gurevich, Maryka Quik, Michele Morari, Manuela Mellone, Fabrizio Gardoni, Elisabetta Tronci, Dominique Guehl, François Tison, Alan R. Crossman, Un Jung Kang, Kathy Steece-Collier, Susan Fox, Manolo Carta, M. Angela Cenci, Erwan Bézard, Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease, Progress in Neurobiology, 2015, 132, 96

    CrossRef

  11. 11
    Lucas T. Woods, Deepa Ajit, Jean M. Camden, Laurie Erb, Gary A. Weisman, Purinergic receptors as potential therapeutic targets in Alzheimer's disease, Neuropharmacology, 2015,

    CrossRef

  12. 12
    Hong X. Ding, Carolyn A. Leverett, Robert E. Kyne, Kevin K.-C. Liu, Sarah J. Fink, Andrew C. Flick, Christopher J. O’Donnell, Synthetic approaches to the 2013 new drugs, Bioorganic & Medicinal Chemistry, 2015, 23, 9, 1895

    CrossRef

  13. 13
    Shin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kanda, The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets, European Journal of Pharmacology, 2015, 766, 25

    CrossRef

  14. 14
    Shin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kanda, The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets, European Journal of Pharmacology, 2015, 747, 160

    CrossRef

  15. 15
    Ruxandra Julia Vorovenci, Angelo Antonini, The efficacy of oral adenosine A2Aantagonist istradefylline for the treatment of moderate to severe Parkinson’s disease, Expert Review of Neurotherapeutics, 2015, 15, 12, 1383

    CrossRef

  16. 16
    Thomas Müller, The safety of istradefylline for the treatment of Parkinson’s disease, Expert Opinion on Drug Safety, 2015, 14, 5, 769

    CrossRef

  17. 17
    Manuela Pilleri, Angelo Antonini, Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease, Expert Opinion on Drug Safety, 2015, 14, 2, 281

    CrossRef

  18. 18
    S. Schipper, M. W. Aalbers, K. Rijkers, A. Swijsen, J. M. Rigo, G. Hoogland, J. S. H. Vles, Tonic GABAA Receptors as Potential Target for the Treatment of Temporal Lobe Epilepsy, Molecular Neurobiology, 2015,

    CrossRef

  19. 19
    Sandrine Camus, Wai Kin D. Ko, Elsa Pioli, Erwan Bezard, Why bother using non-human primate models of cognitive disorders in translational research?, Neurobiology of Learning and Memory, 2015, 124, 123

    CrossRef

  20. 20
    I. Casetta, F. Vincenzi, D. Bencivelli, C. Corciulo, M. Gentile, E. Granieri, P.A. Borea, K. Varani, A2A adenosine receptors and Parkinson's disease severity, Acta Neurologica Scandinavica, 2014, 129, 4
  21. 21
    Annalisa Pinna, Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued, CNS Drugs, 2014, 28, 5, 455

    CrossRef

  22. 22
    Manuel de Lera Ruiz, Yeon-Hee Lim, Junying Zheng, Adenosine A2AReceptor as a Drug Discovery Target, Journal of Medicinal Chemistry, 2014, 57, 9, 3623

    CrossRef

  23. 23
    Koji Yamada, Minoru Kobayashi, Shizuo Shiozaki, Teruko Ohta, Akihisa Mori, Peter Jenner, Tomoyuki Kanda, Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats, Psychopharmacology, 2014, 231, 14, 2839

    CrossRef

  24. 24
    Amaal Al Dakheel, Isabelle Beaulieu-Boire, Susan H Fox, Emerging drugs for levodopa-induced dyskinesia, Expert Opinion on Emerging Drugs, 2014, 19, 3, 415

    CrossRef

  25. 25
    Izaskun Villar-Menéndez, Sílvia Porta, Sandra P. Buira, Thais Pereira-Veiga, Sara Díaz-Sánchez, José Luis Albasanz, Isidre Ferrer, Mairena Martín, Marta Barrachina, Increased striatal adenosine A2A receptor levels is an early event in Parkinson’s disease-related pathology and it is potentially regulated by miR-34b, Neurobiology of Disease, 2014, 69, 206

    CrossRef

  26. 26
    Silvia Cerri, Giovanna Levandis, Giulia Ambrosi, Elena Montepeloso, Gian Filippo Antoninetti, Rafael Franco, José Luis Lanciego, Younis Baqi, Christa E. Müller, Annalisa Pinna, Fabio Blandini, Marie Therese Armentero, Neuroprotective Potential of Adenosine A2A and Cannabinoid CB1 Receptor Antagonists in an Animal Model of Parkinson Disease, Journal of Neuropathology & Experimental Neurology, 2014, 73, 5, 414

    CrossRef

  27. 27
    Eva Schaeffer, Andrea Pilotto, Daniela Berg, Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease, CNS Drugs, 2014, 28, 12, 1155

    CrossRef

  28. 28
    Izaskun Villar-Menéndez, Fabiana Nuñez, Sara Díaz-Sánchez, José Luis Albasanz, Jaume Taura, Víctor Fernández-Dueñas, Isidre Ferrer, Mairena Martín, Francisco Ciruela, Marta Barrachina, Striatal adenosine A2A receptor expression is controlled by S-adenosyl-L-methionine-mediated methylation, Purinergic Signalling, 2014, 10, 3, 523

    CrossRef

  29. 29
    Xiaoyun Zhou, Shivashankar Khanapur, Anja P. Huizing, Rolf Zijlma, Marianne Schepers, Rudi A. J. O. Dierckx, Aren van Waarde, Erik F. J. de Vries, Philip H. Elsinga, Synthesis and Preclinical Evaluation of 2-(2-Furanyl)-7-[2-[4-[4-(2-[11C]methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine-5-amine ([11C]Preladenant) as a PET Tracer for the Imaging of Cerebral Adenosine A2AReceptors, Journal of Medicinal Chemistry, 2014, 57, 21, 9204

    CrossRef

  30. 30
    Shin-ichi Uchida, Tomomi Tashiro, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kanda, The Adenosine A2A-Receptor Antagonist Istradefylline Enhances the Motor Response of L-DOPA Without Worsening Dyskinesia in MPTP-Treated Common Marmosets, Journal of Pharmacological Sciences, 2014, 124, 4, 480

    CrossRef

  31. 31
    Robert A Hauser, C Warren Olanow, Karl D Kieburtz, Emmanuelle Pourcher, Any Docu-Axelerad, Mark Lew, Olexandr Kozyolkin, Ann Neale, Chris Resburg, Uwe Meya, Christopher Kenney, Stephen Bandak, Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial, The Lancet Neurology, 2014, 13, 8, 767

    CrossRef

  32. 32
    Juan C. Giugni, Michael S. Okun, Treatment of advanced Parkinsonʼs disease, Current Opinion in Neurology, 2014, 27, 4, 450

    CrossRef

  33. 33
    Adolfo Ramirez-Zamora, Eric Molho, Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions, Expert Review of Neurotherapeutics, 2014, 14, 1, 93

    CrossRef

  34. 34
    Albert Y. Hung, Michael A. Schwarzschild, Treatment of Parkinson’s Disease: What’s in the Non-dopaminergic Pipeline?, Neurotherapeutics, 2014, 11, 1, 34

    CrossRef

  35. 35
    Santiago Perez-Lloret, Marcelo Merello, Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant, Expert Opinion on Pharmacotherapy, 2014, 15, 8, 1097

    CrossRef

  36. 36
    Tomoyuki Kanda, Shin-ichi Uchida, Adenosine Receptors in Neurology and Psychiatry, 2014,

    CrossRef

  37. 37
    Masahiko Tomiyama, Adenosine Receptors in Neurology and Psychiatry, 2014,

    CrossRef

  38. 38
    Akihisa Mori, Adenosine Receptors in Neurology and Psychiatry, 2014,

    CrossRef

  39. 39
    Peter Jenner, Adenosine Receptors in Neurology and Psychiatry, 2014,

    CrossRef

  40. 40
    Peter Jenner, A cup of coffee a day keeps dyskinesia away?, Movement Disorders, 2013, 28, 3
  41. 41
    Carlos A Pardo, Ashura Buckley, Audrey Thurm, Li-Ching Lee, Arun Azhagiri, David M Neville, Susan E Swedo, A pilot open-label trial of minocycline in patients with autism and regressive features, Journal of Neurodevelopmental Disorders, 2013, 5, 1, 9

    CrossRef

  42. 42
    Yoshikuni Mizuno, Tomoyoshi Kondo, Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease, Movement Disorders, 2013, 28, 8
  43. 43
    Jiang-Fan Chen, Holger K. Eltzschig, Bertil B. Fredholm, Adenosine receptors as drug targets — what are the challenges?, Nature Reviews Drug Discovery, 2013, 12, 4, 265

    CrossRef

  44. 44
    Lars Brichta, Paul Greengard, Marc Flajolet, Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems, Trends in Neurosciences, 2013, 36, 9, 543

    CrossRef

  45. 45
    Koji Yamada, Minoru Kobayashi, Akihisa Mori, Peter Jenner, Tomoyuki Kanda, Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents, Pharmacology Biochemistry and Behavior, 2013, 114-115, 23

    CrossRef

  46. 46
    Anne-Marie A. Wills, Shirley Eberly, Marsha Tennis, Anthony E. Lang, Susan Messing, Daniel Togasaki, Caroline M. Tanner, Cornelia Kamp, Jiang-Fan Chen, David Oakes, Michael P. McDermott, Michael A. Schwarzschild, Caffeine consumption and risk of dyskinesia in CALM-PD, Movement Disorders, 2013, 28, 3
  47. 47
    John D. Salamone, Lyndsey E. Collins-Praino, Marta Pardo, Samantha J. Podurgiel, Younis Baqi, Christa E. Müller, Michael A. Schwarzschild, Mercè Correa, Conditional neural knockout of the adenosine A2A receptor and pharmacological A2A antagonism reduce pilocarpine-induced tremulous jaw movements: Studies with a mouse model of parkinsonian tremor, European Neuropsychopharmacology, 2013, 23, 8, 972

    CrossRef

  48. 48
    Lyndsey E. Collins-Praino, Nicholas E. Paul, Felicia Ledgard, Samantha J. Podurgiel, Rotem Kovner, Younis Baqi, Christa E. Müller, Patrick B. Senatus, John D. Salamone, Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2A antagonism, European Journal of Neuroscience, 2013, 38, 1
  49. 49
    Mayumi Saki, Koji Yamada, Etsuko Koshimura, Katsutoshi Sasaki, Tomoyuki Kanda, In vitro pharmacological profile of the A2A receptor antagonist istradefylline, Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 11, 963

    CrossRef

  50. 50
    Wanqiang Chen, Hongquan Wang, Hongtao Wei, Shuli Gu, Haiping Wei, Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis, Journal of the Neurological Sciences, 2013, 324, 1-2, 21

    CrossRef

  51. 51
    Rosselle Dungo, Emma D. Deeks, Istradefylline: First Global Approval, Drugs, 2013, 73, 8, 875

    CrossRef

  52. 52
    Stewart A. Factor, Kenneth Wolski, Daniel M. Togasaki, Susan Huyck, Marc Cantillon, T.W. Ho, Robert A. Hauser, Emmanuelle Pourcher, Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease, Movement Disorders, 2013, 28, 6
  53. 53
    Li Huang, Dong-dong Wu, Lei Zhang, Lin-yin Feng, Modulation of A2a receptor antagonist on D2 receptor internalization and ERK phosphorylation, Acta Pharmacologica Sinica, 2013, 34, 10, 1292

    CrossRef

  54. 54
    Susan H. Fox, Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease, Drugs, 2013, 73, 13, 1405

    CrossRef

  55. 55
    Manuela Jörg, Jeremy Shonberg, Frankie S. Mak, Neil D. Miller, Elizabeth Yuriev, Peter J. Scammells, Ben Capuano, Novel adenosine A2A receptor ligands: A synthetic, functional and computational investigation of selected literature adenosine A2A receptor antagonists for extending into extracellular space, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 11, 3427

    CrossRef

  56. 56
    Lorraine V. Kalia, Jonathan M. Brotchie, Susan H. Fox, Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials, Movement Disorders, 2013, 28, 2
  57. 57
    Carlos Zúñiga-Ramírez, Federico Micheli, Preladenant: an adenosine A2Areceptor antagonist for Parkinson’s disease, Future Neurology, 2013, 8, 6, 639

    CrossRef

  58. 58
    Thomas Müller, Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations, Expert Opinion on Drug Metabolism & Toxicology, 2013, 9, 8, 1015

    CrossRef

  59. 59
    Mietha M. Van der Walt, Gisella Terre’Blanche, Anél Petzer, Anna C.U. Lourens, Jacobus P. Petzer, The adenosine A2A antagonistic properties of selected C8-substituted xanthines, Bioorganic Chemistry, 2013, 49, 49

    CrossRef

  60. 60
    Philippe Huot, Tom H. Johnston, Tessa Snoeren, James B. Koprich, Michael P. Hill, Susan H. Fox, Jonathan M. Brotchie, Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque, European Journal of Neuroscience, 2013, 37, 5
  61. 61
    Fernando Pagan, Jill Farmer, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  62. 62
    Fernando L. Pagan, Jill Giordano Farmer, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  63. 63
    Micaela Morelli, Fabio Blandini, Nicola Simola, Robert A. Hauser, A2AReceptor Antagonism and Dyskinesia in Parkinson’s Disease, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  64. 64
    Patrick Hickey, Mark Stacy, Adenosine A2A Antagonists in Parkinson’s Disease: What’s Next?, Current Neurology and Neuroscience Reports, 2012, 12, 4, 376

    CrossRef

  65. 65
    Monalisa W Pereira, Paulo Correia-de-Sá, Wilson Alves-Do-Prado, Adenosine A2A receptor antagonists are broad facilitators of antinicotinic neuromuscular blockade monitored either with 2 Hz train-of-four or 50 Hz tetanic stimuli, Clinical and Experimental Pharmacology and Physiology, 2012, 39, 10
  66. 66
    James W. Bogenpohl, Stefanie L. Ritter, Randy A. Hall, Yoland Smith, Adenosine A2A receptor in the monkey basal ganglia: Ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum, Journal of Comparative Neurology, 2012, 520, 3
  67. 67
    J. Guridi, R. González-Redondo, J. A. Obeso, Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  68. 68
    Werner Poewe, Philipp Mahlknecht, Joseph Jankovic, Emerging therapies for Parkinsonʼs disease, Current Opinion in Neurology, 2012, 25, 4, 448

    CrossRef

  69. 69
    Emmanuelle Pourcher, Hubert H. Fernandez, Mark Stacy, Akihisa Mori, Rocco Ballerini, Philip Chaikin, Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study, Parkinsonism & Related Disorders, 2012, 18, 2, 178

    CrossRef

  70. 70
    Ariane Park, Mark Stacy, Istradefylline for the treatment of Parkinson's disease, Expert Opinion on Pharmacotherapy, 2012, 13, 1, 111

    CrossRef

  71. 71
    John Seibyl, David Russell, Danna Jennings, Kenneth Marek, Neuroimaging Over the Course of Parkinson's Disease: From Early Detection of the At-Risk Patient to Improving Pharmacotherapy of Later-Stage Disease, Seminars in Nuclear Medicine, 2012, 42, 6, 406

    CrossRef

  72. 72
    Fabio Blandini, Marie-Therese Armentero, New pharmacological avenues for the treatment ofl-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors, Expert Opinion on Investigational Drugs, 2012, 21, 2, 153

    CrossRef

  73. 73
    Yoland Smith, Thomas Wichmann, Stewart A Factor, Mahlon R DeLong, Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa, Neuropsychopharmacology, 2012, 37, 1, 213

    CrossRef

  74. 74
    William Knebel, Niranjan Rao, T. Uchimura, Akihisa Mori, Jeannine Fisher, Marc R. Gastonguay, Philip Chaikin, Population Pharmacokinetic-Pharmacodynamic Analysis of Istradefylline in Patients With Parkinson Disease, The Journal of Clinical Pharmacology, 2012, 52, 10
  75. 75
    Lyndsey E. Collins, Thomas N. Sager, Anette G. Sams, Adam Pennarola, Russell G. Port, Mona Shahriari, John D. Salamone, The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade, Pharmacology Biochemistry and Behavior, 2012, 100, 3, 498

    CrossRef

  76. 76
    Jessica L. Santerre, Eric J. Nunes, Rotem Kovner, Chelsea E. Leser, Patrick A. Randall, Lyndsey E. Collins-Praino, Laura Lopez Cruz, Merce Correa, Younis Baqi, Christa E. Müller, John D. Salamone, The novel adenosine A2A antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions, Pharmacology Biochemistry and Behavior, 2012, 102, 4, 477

    CrossRef

  77. 77
    Kemal Ugur Tufekci, Ralph Meuwissen, Sermin Genc, Kursad Genc, Advances in Protein Chemistry and Structural Biology Volume 88, 2012,

    CrossRef

  78. 78
    Danna Jennings, David Russell, Ken Marek, John Seibyl, Parkinson's Disease, Second Edition, 2012,

    CrossRef

  79. 79
    Leo Metman, Christina Vaughan, Parkinson's Disease, Second Edition, 2012,

    CrossRef

  80. 80
    Stefania Gessi, Stefania Merighi, Debora Fazzi, Angela Stefanelli, Katia Varani, Pier Andrea Borea, Adenosine receptor targeting in health and disease, Expert Opinion on Investigational Drugs, 2011, 20, 12, 1591

    CrossRef

  81. 81
    Robert D. Altman, Anthony E. Lang, Ronald B. Postuma, Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study, Movement Disorders, 2011, 26, 13
  82. 82
    Peter LeWitt, Lonni Schultz, Peggy Auinger, Mei Lu, CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease, Brain Research, 2011, 1408, 88

    CrossRef

  83. 83
    C. Di Caudo, M.R. Luquin, Enfermedad de Parkinson, Medicine - Programa de Formación Médica Continuada Acreditado, 2011, 10, 73, 4944

    CrossRef

  84. 84
    Karin Wirdefeldt, Hans-Olov Adami, Philip Cole, Dimitrios Trichopoulos, Jack Mandel, Epidemiology and etiology of Parkinson’s disease: a review of the evidence, European Journal of Epidemiology, 2011, 26, S1, 1

    CrossRef

  85. 85
    Robert A. Hauser, Future Treatments for Parkinson's Disease: Surfing the PD Pipeline, International Journal of Neuroscience, 2011, 121, S2, 53

    CrossRef

  86. 86
    Mahmoud M. Iravani, Peter Jenner, Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation, Journal of Neural Transmission, 2011, 118, 12, 1661

    CrossRef

  87. 87
    T. Santhosh Kumar, Shilpi Mishra, Francesca Deflorian, Lena S. Yoo, Khai Phan, Miklos Kecskés, Angela Szabo, Bidhan Shinkre, Zhan-Guo Gao, William Trenkle, Kenneth A. Jacobson, Molecular probes for the A2A adenosine receptor based on a pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine scaffold, Bioorganic & Medicinal Chemistry Letters, 2011, 21, 9, 2740

    CrossRef

  88. 88
    Lucia Frau, Franco Borsini, Jadwiga Wardas, Amit S. Khairnar, Nicoletta Schintu, Micaela Morelli, Neuroprotective and anti-inflammatory effects of the adenosine A2A receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease, Synapse, 2011, 65, 3
  89. 89
    Philippe Huot, Susan H Fox, Nondopaminergic treatments for Parkinson’s disease, Neurodegenerative Disease Management, 2011, 1, 6, 491

    CrossRef

  90. 90
    Catherine J. Wei, Wei Li, Jiang-Fan Chen, Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies, Biochimica et Biophysica Acta (BBA) - Biomembranes, 2011, 1808, 5, 1358

    CrossRef

  91. 91
    Nikoletta Szabó, Zsigmond Tamás Kincses, László Vécsei, Novel therapy in Parkinson's disease: adenosine A2Areceptor antagonists, Expert Opinion on Drug Metabolism & Toxicology, 2011, 7, 4, 441

    CrossRef

  92. 92
    Lyndsey E. Collins, Nicholas E. Paul, Shams F. Abbas, Chelsea E. Leser, Samantha J. Podurgiel, Daniel J. Galtieri, James J. Chrobak, Younis Baqi, Christa E. Müller, John D. Salamone, Oral tremor induced by galantamine in rats: A model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease, Pharmacology Biochemistry and Behavior, 2011, 99, 3, 414

    CrossRef

  93. 93
    Marie Therese Armentero, Annalisa Pinna, Sergi Ferré, José Luis Lanciego, Christa E. Müller, Rafael Franco, Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease, Pharmacology & Therapeutics, 2011, 132, 3, 280

    CrossRef

  94. 94
    William Knebel, Niranjan Rao, Tatsuo Uchimura, Akihisa Mori, Jeannine Fisher, Marc R. Gastonguay, Philip Chaikin, Population Pharmacokinetic Analysis of Istradefylline in Healthy Subjects and in Patients With Parkinson's Disease, The Journal of Clinical Pharmacology, 2011, 51, 1
  95. 95
    Robert A Hauser, Marc Cantillon, Emmanuelle Pourcher, Federico Micheli, Vincent Mok, Marco Onofrj, Susan Huyck, Kenneth Wolski, Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial, The Lancet Neurology, 2011, 10, 3, 221

    CrossRef

  96. 96
    Wassilios G. Meissner, Mark Frasier, Thomas Gasser, Christopher G. Goetz, Andres Lozano, Paola Piccini, José A. Obeso, Olivier Rascol, Anthony Schapira, Valerie Voon, David M. Weiner, François Tison, Erwan Bezard, Priorities in Parkinson's disease research, Nature Reviews Drug Discovery, 2011, 10, 5, 377

    CrossRef

  97. 97
    Christa E. Müller, Kenneth A. Jacobson, Recent developments in adenosine receptor ligands and their potential as novel drugs, Biochimica et Biophysica Acta (BBA) - Biomembranes, 2011, 1808, 5, 1290

    CrossRef

  98. 98
    Werner J. Geldenhuys, Moussa B.H. Youdim, Richard T. Carroll, Cornelis J. Van der Schyf, The emergence of designed multiple ligands for neurodegenerative disorders, Progress in Neurobiology, 2011, 94, 4, 347

    CrossRef

  99. 99
    S. Maranis, S. Tsouli, S. Konitsiotis, Treatment of motor symptoms in advanced Parkinson's disease: A practical approach, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 8, 1795

    CrossRef

  100. 100
    Angelo Antonini, Pablo Martinez-Martin, Ray K. Chaudhuri, Marcelo Merello, Robert Hauser, Regina Katzenschlager, Per Odin, Mark Stacy, Fabrizio Stocchi, Werner Poewe, Oliver Rascol, Cristina Sampaio, Anette Schrag, Glenn T. Stebbins, Christopher G. Goetz, Wearing-off scales in Parkinson's disease: Critique and recommendations, Movement Disorders, 2011, 26, 12
  101. 101
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  102. 102
    Stefania Gessi, Stefania Merighi, Katia Varani, Pier Andrea Borea, Pharmacology of Purine and Pyrimidine Receptors, 2011,

    CrossRef

  103. 103
    Cornelis J. Van der Schyf, Werner J. Geldenhuys, Monoamine Oxidase and their Inhibitors, 2011,

    CrossRef

  104. 104
    Stewart Factor, Margery H. Mark, Ray Watts, Lynn Struck, Akihisa Mori, Rocco Ballerini, Neil M. Sussman, A long-term study of istradefylline in subjects with fluctuating Parkinson's disease, Parkinsonism & Related Disorders, 2010, 16, 6, 423

    CrossRef

  105. 105
    David J. Brooks, Spyridon Papapetropoulos, Francois Vandenhende, Davorka Tomic, Ping He, Alex Coppell, Gilmore O'Neill, An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers, Clinical Neuropharmacology, 2010, 33, 2, 55

    CrossRef

  106. 106
    Hélio Vitoriano Nobre, Geanne Matos de Andrade Cunha, Lissiana Magna de Vasconcelos, Hemerson Iury Ferreira Magalhães, Raimundo Nogueira Oliveira Neto, Flávio Damasceno Maia, Manoel Odorico de Moraes, L. Kalyne A. Moreira Leal, Glauce Socorro de Barros Viana, Caffeine and CSC, adenosine A2A antagonists, offer neuroprotection against 6-OHDA-induced neurotoxicity in rat mesencephalic cells, Neurochemistry International, 2010, 56, 1, 51

    CrossRef

  107. 107
    Yoshikuni Mizuno, Kazuko Hasegawa, Tomoyoshi Kondo, Sadako Kuno, Mitsutoshi Yamamoto, Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study, Movement Disorders, 2010, 25, 10
  108. 108
    Sandra P. Buira, José Luis Albasanz, Guido Dentesano, Jesús Moreno, Mairena Martín, Isidre Ferrer, Marta Barrachina, DNA methylation regulates adenosine A2A receptor cell surface expression levels, Journal of Neurochemistry, 2010, 112, 5
  109. 109
    J Stagg, M J Smyth, Extracellular adenosine triphosphate and adenosine in cancer, Oncogene, 2010, 29, 39, 5346

    CrossRef

  110. 110
    Li Rebekah Feng, Kathleen A. Maguire-Zeiss, Gene Therapy in Parkinsonʼs Disease, CNS Drugs, 2010, 24, 3, 177

    CrossRef

  111. 111
    Amy Yang, Abraham A. Palmer, Harriet de Wit, Genetics of caffeine consumption and responses to caffeine, Psychopharmacology, 2010, 211, 3, 245

    CrossRef

  112. 112
    H.H. Fernandez, D.R. Greeley, R.M. Zweig, J. Wojcieszek, A. Mori, N.M. Sussman, Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial, Parkinsonism & Related Disorders, 2010, 16, 1, 16

    CrossRef

  113. 113
    Kerstin Buck, Boris Ferger, l-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective, Drug Discovery Today, 2010, 15, 19-20, 867

    CrossRef

  114. 114
    Elisabeth Wolf, Klaus Seppi, Regina Katzenschlager, Guenter Hochschorner, Gerhard Ransmayr, Petra Schwingenschuh, Erwin Ott, Iris Kloiber, Dietrich Haubenberger, Eduard Auff, Werner Poewe, Long-term antidyskinetic efficacy of amantadine in Parkinson's disease, Movement Disorders, 2010, 25, 10
  115. 115
    Lyndsey E. Collins, Daniel J. Galtieri, Lise T. Brennum, Thomas N. Sager, Jörg Hockemeyer, Christa E. Müller, James R. Hinman, James J. Chrobak, John D. Salamone, Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX, Pharmacology Biochemistry and Behavior, 2010, 94, 4, 561

    CrossRef

  116. 116
    Pratibha Mehta Luthra, Chandra Bhushan Mishra, Pawan Kumar Jha, Sandeep Kumar Barodia, Synthesis of novel 7-imino-2-thioxo-3,7-dihydro-2H-thiazolo [4,5-d] pyrimidine derivatives as adenosine A2A receptor antagonists, Bioorganic & Medicinal Chemistry Letters, 2010, 20, 3, 1214

    CrossRef

  117. 117
    Osamu Saku, Mayumi Saki, Masako Kurokawa, Ken Ikeda, Takuya Takizawa, Noriaki Uesaka, Synthetic studies on selective adenosine A2A receptor antagonists: Synthesis and structure–activity relationships of novel benzofuran derivatives, Bioorganic & Medicinal Chemistry Letters, 2010, 20, 3, 1090

    CrossRef

  118. 118
    Osamu Saku, Mayumi Saki, Masako Kurokawa, Ken Ikeda, Shin-ichi Uchida, Takuya Takizawa, Noriaki Uesaka, Synthetic studies on selective adenosine A2A receptor antagonists. Part II: Synthesis and structure–activity relationships of novel benzofuran derivatives, Bioorganic & Medicinal Chemistry Letters, 2010, 20, 12, 3768

    CrossRef

  119. 119
    Tom H. Johnston, Susan H. Fox, Matthew J. Piggott, Juha-Matti Savola, Jonathan M. Brotchie, The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates, Movement Disorders, 2010, 25, 13
  120. 120
    Alessandro Stefani, Mariangela Pierantozzi, Giacomo Koch, Salvatore Galati, Paolo Stanzione, Therapy for dyskinesias in Parkinson’s disease patients, Future Neurology, 2010, 5, 2, 277

    CrossRef

  121. 121
    Micaela Morelli, Nicola Simola, Patrizia Popoli, Anna R. Carta, Handbook of Basal Ganglia Structure and Function, 2010,

    CrossRef

  122. 122
    Micaela Morelli, Anna R. Carta, Anil Kachroo, Michael A. Schwarzschild, Recent Advances in Parkinson’s Disease: Basic Research, 2010,

    CrossRef

  123. 123
    P. Jenner, A. Mori, R. Hauser, M. Morelli, B.B. Fredholm, J.F. Chen, Adenosine, adenosine A2A antagonists, and Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, 6, 406

    CrossRef

  124. 124
    Roger J. Gillespie, Samantha J. Bamford, Suneel Gaur, Allan M. Jordan, Joanne Lerpiniere, Howard L. Mansell, Gemma C. Stratton, Antagonists of the human A2A receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides, Bioorganic & Medicinal Chemistry Letters, 2009, 19, 10, 2664

    CrossRef

  125. 125
    Roger J. Gillespie, Samantha J. Bamford, Alex Clay, Suneel Gaur, Tim Haymes, Philip S. Jackson, Allan M. Jordan, Burkhard Klenke, Stefania Leonardi, Jeanette Liu, Howard L. Mansell, Sean Ng, Mona Saadi, Heather Simmonite, Gemma C. Stratton, Richard S. Todd, Douglas S. Williamson, Ian A. Yule, Antagonists of the human A2A receptor. Part 6: Further optimization of pyrimidine-4-carboxamides, Bioorganic & Medicinal Chemistry, 2009, 17, 18, 6590

    CrossRef

  126. 126
    Jacobus P. Petzer, Neal Castagnoli, Michael A. Schwarzschild, Jiang -Fan Chen, Cornelis J. Schyf, Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease, Neurotherapeutics, 2009, 6, 1, 141

    CrossRef

  127. 127
    Krystyna Gołembiowska, Anna Dziubina, Magdalena Kowalska, Katarzyna Kamińska, Effect of Adenosine A2A Receptor Antagonists on l-DOPA-Induced Hydroxyl Radical Formation in Rat Striatum, Neurotoxicity Research, 2009, 15, 2, 155

    CrossRef

  128. 128
    Catarina A. R. V. Gomes, Patrícia F. Simões, Paula M. Canas, César Quiroz, Ana M. Sebastião, Sergi Ferré, Rodrigo A. Cunha, Joaquim A. Ribeiro, GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A2A receptors, Journal of Neurochemistry, 2009, 108, 5
  129. 129
    Sai-jun Zhou, Mei-er Zhu, Dan Shu, Xun-ping Du, Xiu-hua Song, Xiao-tong Wang, Rong-yuan Zheng, Xiao-hong Cai, Jiang-fan Chen, Jin-cai He, Preferential enhancement of working memory in mice lacking adenosine A2A receptors, Brain Research, 2009, 1303, 74

    CrossRef

  130. 130
    Y.-N. Wu, J.-J.J. Chen, L.-Q. Zhang, B.I. Hyland, Regulation of hind-limb tone by adenosine A2A receptor in rats, Neuroscience, 2009, 159, 4, 1408

    CrossRef

  131. 131
    Takuma Mihara, Akinori Iwashita, Nobuya Matsuoka, A novel adenosine A1 and A2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs, Behavioural Brain Research, 2008, 194, 2, 152

    CrossRef

  132. 132
    Joseph Jankovic, Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?, Annals of Neurology, 2008, 63, 3
  133. 133
    Istradefylline reduces motor fluctuations in Parkinson's disease, Nature Clinical Practice Neurology, 2008, 4, 6, 291

    CrossRef

  134. 134
    Sergi Ferré, La cafeína en la enfermedad de Parkinson, Medicina Clínica, 2008, 131, 18, 710

    CrossRef

  135. 135
    Susan H Fox, Jonathan M Brotchie, Anthony E Lang, Non-dopaminergic treatments in development for Parkinson's disease, The Lancet Neurology, 2008, 7, 10, 927

    CrossRef

  136. 136
    Karl Strecker, Johannes Schwarz, Parkinson's disease: emerging pharmacotherapy, Expert Opinion on Emerging Drugs, 2008, 13, 4, 573

    CrossRef

  137. 137
    Robert A. Hauser, Lisa M. Shulman, Joel M. Trugman, John W. Roberts, Akihisa Mori, Rocco Ballerini, Neil M. Sussman, Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations, Movement Disorders, 2008, 23, 15
  138. 138
    David B Sommer, Mark A Stacy, What’s in the pipeline for the treatment of Parkinson’s disease?, Expert Review of Neurotherapeutics, 2008, 8, 12, 1829

    CrossRef

  139. 139
    Yousheng Xiao, Lu Gan, Jin Wang, Adenosine A2A receptor antagonist istradefylline for levodopa-induced complications in Parkinson's disease, The Cochrane Library,
  140. 140
    Jing-Wei Lim, Eng-King Tan, Coffee and Parkinson's Disease,
  141. 141
    S. Elizabeth Zauber, Christopher G. Goetz, Dyskinesias in Parkinsonian Syndromes,
  142. 142
    Susan H. Fox, Jonathan M. Brotchie, Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease,